Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...
European regulatory committee rejects Lilly's Alzheimer's disease treatment due to potential risks of brain bleeding and ...
The EMA’s Committee for Medicinal Products for Human Use said that a phase 3 study in children aged 3-14 years demonstrated ...
Eli Lilly, which is seeking European approval of Kisunla for the treatment of early symptomatic Alzheimer's, said it will seek re-examination by CHMP. The Indianapolis drugmaker said it remains ...
The EMA has recommended refusing marketing authorization for donanemab, a monoclonal antibody against amyloid beta, in the ...
NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Thursday recommended against marketing authorization for Eli Llilly's Alzheimer's drug Kisunla ...
After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease ...
From humble beginnings in a cramped office in the courthouse, to its own dedicated offices on W Harris St., Sullivan County's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback